• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Glaukos touts economic savings in dual iStent study

Glaukos touts economic savings in dual iStent study

May 23, 2017 By Fink Densford

Glaukos logo

Glaukos (NYSE:GKOS) today touted data from an economic analysis of elevated intraocular pressure treatments in open-angle glaucoma patients, which reported low cost associated with the use of its iStent devices.

The economic analysis study aimed to analyze direct cost for 3 treatment options for treating patients with elevated IOP open-angle glaucoma, including selective laser trabeculoplasty, topical glaucoma medication and the use of 2 iStent trabecular micro-bypass stents.

Results indicated a lower projected average cumulative cost at 5 years with the use of 2 iStent devices when compared to the other treatment options, according to San Clemente, Calif.-based Glaukos.

“While numerous international studies have shown the ability of two trabecular meshwork stents to effectively control IOP in open-angle glaucoma patients, this analysis is the first to reveal the potential cost efficiency of trabecular stenting, especially over longer time horizons. Our research indicates that the two-stent treatment option may reduce glaucoma-related health resource use and contribute to direct cost savings, particularly when compared to topical medication only, which is the most commonly used treatment option today but is often ineffective due to high rates of patient non-compliance,” study author Dr. John Berdahl said in a prepared statement.

Projected average cumulative cost at 5 years was $4,420 for the 2 stent procedure, lower than the projected $4,730 for SLT treatment or $6,217 for topical medication alone. Data from the study indicated that the 2-stent procedure had the highest initial year cost and the lowest annual marginal cost for each subsequent year.

“Our core strategy is to provide a full complement of micro-scale treatment options that can effectively manage IOP and overcome many of the drawbacks of conventional therapies. Peer-reviewed study results like these help to illustrate the potential for our technologies to offer important clinical and economic benefits for physicians, patients and the healthcare system,” CEO & prez Thomas Burns said in a press release.

Filed Under: Clinical Trials, Optical/Ophthalmic Tagged With: Glaukos

More recent news

  • Mount Sinai adopts Flosonics wearable ultrasound device
  • GE HealthCare launches next-gen intraoperative ultrasound
  • Philips launches new point-of-care ultrasound system
  • Medtronic to invest $50M in India Diabetes center
  • Corvia Medical raises $55M as it seeks FDA nod for atrial shunt

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy